Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. (Nasdaq: CBLL) is a medical technology company that develops the Ceribell System, a point-of-care electroencephalography (EEG) platform for patients with serious neurological conditions in acute care settings. This news page aggregates company announcements, clinical and regulatory milestones, and financial updates that relate to CeriBell’s AI-powered brain monitoring technology.
Readers can find coverage of key regulatory events, such as FDA 510(k) clearances for the company’s next-generation Clarity® algorithm to detect electrographic seizures in pre-term neonates through adults and for its proprietary delirium screening and monitoring solution. The news feed also includes information on the FDA Breakthrough Device Designation granted to CeriBell’s Large Vessel Occlusion (LVO) stroke detection monitor, which uses existing Ceribell hardware and an AI-based algorithm to interpret EEG signals for early LVO stroke detection in hospitalized patients.
In addition to regulatory developments, CeriBell’s news includes quarterly financial results that distinguish between product and subscription revenue, updates on adoption of the Ceribell System in intensive care units and emergency rooms across the U.S., and disclosures about corporate agreements and intellectual property matters. Examples include supply agreements for EEG headbands, licensing arrangements with Stanford University, and patent-related legal actions.
Investors and healthcare professionals can also follow announcements about CeriBell’s participation in healthcare and medtech conferences, as well as board and governance updates. This page offers a centralized view of how the company’s point-of-care EEG platform, AI algorithms, and commercial activities are evolving over time, providing context for CBLL stock watchers and those tracking advancements in neurocritical care devices.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has scheduled its Q1 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results.
Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 7370458. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.
Ceribell (Nasdaq: CBLL) has received FDA 510(k) clearance for its Clarity™ algorithm, becoming the first and only AI-powered point-of-care EEG system cleared to detect electrographic seizures in patients aged 1 year and older. The clearance was supported by EEG data from over 1,700 patients, marking the largest validation dataset ever used for FDA clearance of a seizure detection system.
The Clarity algorithm works with Ceribell's existing EEG headbands and enables rapid, bedside detection, diagnosis, and treatment of non-convulsive seizures in children experiencing neurological emergencies. Clinical guidelines recommend initiating EEG within 15-60 minutes of suspected continuous non-convulsive seizures, but children often face hours or days of waiting for assessment. This technology aims to address this critical gap by providing immediate bedside neurological assessment.
Ceribell (NASDAQ: CBLL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $18.5 million, up 41% year-over-year, while full-year revenue grew 45% to $65.4 million. The company maintained robust gross margins of 88% in Q4 and 87% for the full year.
Key highlights include reaching 529 total active accounts and treating over 200,000 patients. However, operating expenses increased 49% to $29.1 million in Q4, resulting in a net loss of $12.6 million ($0.40 per share). Full-year net loss was $40.5 million ($3.39 per share).
The company ended 2024 with $194.4 million in cash and cash equivalents. Looking ahead, Ceribell projects 2025 revenue between $81-85 million, representing 24-30% growth. The company also submitted a 510(k) application for its pediatric Clarity™ algorithm to the FDA.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., along with CFO Scott Blumberg, will engage in a fireside chat scheduled for March 3, 2025, at 6:50 AM PST / 9:50 AM EST.
Interested parties can access both live and archived versions of the presentation through the Investor Relations section of Ceribell's website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has announced its upcoming financial results release. The company will disclose its fourth quarter and full year 2024 financial results after market close on February 25, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 3782735. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jane Chao, Ph.D., CEO and Co-founder, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST.
The presentation will be accessible through a live and archived webcast in the Investor Relations section of Ceribell's website. The company focuses on revolutionizing the diagnosis and management of serious neurological conditions through innovative medical technology solutions.
Ceribell (Nasdaq: CBLL) announced two key leadership appointments: Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing. Rodenbush brings 25+ years of HR experience and will lead the People & Culture team, having previously served as CPO at Meltwater. Price, with 25+ years in medical device industry experience, will focus on market development and penetration, coming from roles at VitalConnect, Medtronic, and Abbott. The appointments aim to support Ceribell's expansion of its AI-powered EEG neurodiagnostic system, addressing a significant market where up to one-third of ICU patients risk nonconvulsive seizures.
Ceribell (Nasdaq: CBLL), a medical technology company, reported third quarter 2024 financial results, showcasing a 48% increase in total revenue to $17.2 million compared to Q3 2023. Gross margin improved to 87% from 84% in the same period last year. The company ended the quarter with 504 active accounts and completed an IPO, raising $188 million in net proceeds. Product revenue rose by 52% to $13.3 million, while subscription revenue increased by 36% to $3.9 million. Despite these gains, operating expenses surged by 48% to $24.9 million, leading to a net loss of $10.4 million for the quarter, up from $7.1 million in Q3 2023. Cash and cash equivalents stood at $14.1 million as of September 30, 2024. Ceribell projects full-year 2024 revenue between $64.2 million and $64.7 million, marking a growth of 42% to 43% over the prior year.
Ceribell (NASDAQ: CBLL) has received Authority to Operate (ATO) from the Department of Veterans Affairs, enabling full deployment of its point-of-care EEG technology across VA hospitals. This authorization allows Ceribell to leverage VA Wi-Fi networks for remote access to EEG reports and data sharing between locations. The system, which has been used in certain VA facilities since 2018, aims to reduce costly ICU admissions and intra-facility patient transfers while supporting timely interventions for veterans, who face elevated risks of seizure disorders. The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring, and has been adopted by over 500 hospitals, serving more than 100,000 patients.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. CFO Scott Blumberg will engage in a fireside chat on Thursday, November 21, 2024, at 10:00 a.m. PST / 1:00 p.m. EST. The event will be accessible via live and archived webcast through Ceribell's Investor Relations website section.